Table 1.
Study cohort | Year | Study region | Ethnicity | Patients/controls | Age, years (median, range) | Cancer type | Control group | TNM | Cut-off | Method | Sensitivity | Specificity |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Duan et al. 21 | 2020 | China | Asian | 34/20 | 59 (30–81) | NSCLC | Healthy | I | 1 | FISH | 43.18 | 100 |
He et al.25 | 2020 | China | Asian | 24/72 | 59.4 (25–85) | NSCLC | Healthy | I–II | 1 | FISH | 62.5 | 100 |
Li et al.27 | 2019 | China | Asian | 174/90 | 58.5 | LC | Healthy/BLD | I–IV | 2/3.2 mL | FISH | 68.39 | 100 |
Gu et al.24 | 2020 | China | Asian | 140/140 | 65.5 | NSCLC | Healthy | I–II | NR | FISH | 67.1 | 80 |
Zhang et al.33 | 2019 | China | Asian | 91/20 | 69±5.9 | LC | Healthy/BLD | III–IV | 1 | FISH | 61.5 | 100 |
Manjunath et al.13 | 2019 | America | Caucasian | 29/20 | 56.55±12.04 | NSCLC | Healthy | I–IV | 21 | FISH | 41.4 | 100 |
Zhou et al.35 QJ1 | 2019 | China | Asian | 197/63 | 64.26 (36–84) | LC | BLD | I–IV | 8.3 U/3 mL | PCR | 78.6 | 78.4 |
Zhou et al.35 QJ2 | 2019 | China | Asian | 93/29 | 61.4 | LC | BLD | I–IV | 8.3 U/3 mL | PCR | 82.7 | 68.8 |
Qian et al.28 | 2018 | China | Asian | 200/50 | NR | LC | Healthy | I–IV | 3.5/mL | FISH | 86 | 98 |
Chen et al.17 | 2018 | China | Asian | 41/10 | 59.34±11.72 | NSCLC | Healthy | NR | 1/2 ml | PCR | 0.732 | 100 |
Gao et al.23 | 2018 | China | Asian | 143/42 | N | LC | Healthy | I–IV | 2.25/mL | PCR | 72 | 97.6 |
Ye et al.31 | 2019 | China | Asian | 85/30 | 61 (44–71) | LC | Healthy | NR | 1/7.5 ml | FISH | 92.9 | 100 |
Xue et al.30 | 2018 | China | Asian | 72/26 | 56 (32–77) | NSCLC | Healthy/BLD | I–IV | 8.7 U/3 mL | PCR | 81.94 | 73.08 |
Zhong et al.34 | 2018 | China | Asian | 241/61 | NR | LC | BLD | I–IV | 1.5 | FISH | 90.5 | 86.9 |
Fiorelli et al.22 | 2015 | Italy | Caucasian | 60/17 | 62.3 (32–87) | NSCLC | BLD | I–IV | 25 | IHC | 89 | 100 |
Chen et al.18 X1 | 2015 | China | Asian | 236/141 | 71 (48–91) | NSCLC | Healthy/BLD | I–IV | 8.93 U/3 mL | PCR | 72.46 | 88.65 |
Chen et al.18 X2 | 2015 | China | Asian | 237/142 | 58 | NSCLC | Healthy/BLD | I–IV | 8.93 U/3 mL | PCR | 76.37 | 82.39 |
Chen et al.19 | 2014 | China | Asian | 50/42 | 63 (33–82) | LC | Healthy/BLD | I–III | 2/3.2 mL | FISH | 84 | 97.6 |
Yu et al.32 | 2013 | China | Asian | 153/113 | 60 (21–81) | NSCLC | Healthy/BLD | I–IV | 8.64 U | PCR | 73.2 | 84.1 |
Lou et al.16 | 2013 | China | Asian | 33/44 | 57 (27–79) | NSCLC | Healthy/BLD | I–III | 8.5 U | PCR | 81.8 | 93.2 |
Devriese et al.20 | 2012 | America | Caucasian | 46/46 | 59 (33–82) | NSCLC | Healthy | IIIb–IV | 1 | PCR | 46 | 93 |
Hofman et al.26 | 2011 | France | Caucasian | 210/40 | 59 (23–83) | NSCLC | Healthy | I–IV | 2 | IHC | 39 | 100 |
Tanaka et al.29 | 2009 | Japan | Asian | 125/25 | 61 (43–88) | LC | BLD | I–IV | 1 | FISH | 30.4 | 88 |
BLD, benign lung disease; NR, not reported; NSCLC, non-small cell lung cancer; LC lung cancer; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction.